1. Impact of Nonsynonymous Single-Nucleotide Variations on Post-Translational Modification Sites in Human Proteins
   Naila Gulzar et al, 2017, Protein Bioinformatics CrossRef
2. Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer
   Sandra P. Nunes et al, 2024, Cell Death Discovery CrossRef
3. Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells
   Wei Xu et al, 2018, Cancer Letters CrossRef
4. Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma
   Sumati Gupta et al, 2019, Molecular Cancer Therapeutics CrossRef
5. Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet
   Victor G. Martinez et al, 2019, Frontiers in Genetics CrossRef
6. Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies
   Breann C. Sommer et al, 2018, Bladder Cancer CrossRef
7. Epigenetic therapy in urologic cancers: an update on clinical trials
   Inês Faleiro et al, 2017, Oncotarget CrossRef
8. The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells
   Lina Song et al, 2021, Journal of Investigative Dermatology CrossRef
9. 5′-Iodotubercidin represses insulinoma-associated-1 expression, decreases cAMP levels, and suppresses human neuroblastoma cell growth
   Chiachen Chen et al, 2019, Journal of Biological Chemistry CrossRef
10. Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M
    Qingdi Quentin Li et al, 2018, Cellular and Molecular Life Sciences CrossRef
11. MEK is a promising target in the basal subtype of bladder cancer
    Nathan M. Merrill et al, 2020, Oncotarget CrossRef
12. Implications of Chromatin Modifier Mutations in Epigenetic Regulation of Bladder Cancer
    Burcu Akman et al, 2022, Urologic Cancers CrossRef
13. Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)
    Adriana Celesia et al, 2023, International Journal of Molecular Sciences CrossRef
14. Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
    Aikaterini F. Giannopoulou et al, 2019, International Journal of Molecular Sciences CrossRef
15. Epigenetic Priming and Development of New Combination Therapy Approaches
    Sarah Meneceur et al, 2023, Urothelial Carcinoma CrossRef
16. Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs
    Christopher M. Fulkerson et al, 2017, International Journal of Genomics CrossRef
17. The Seed Repair Response during Germination: Disclosing Correlations between DNA Repair, Antioxidant Response, and Chromatin Remodeling in Medicago truncatula
    Andrea Pagano et al, 2017, Frontiers in Plant Science CrossRef
18. New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
    Daniela Criscuolo et al, 2019, Journal of Experimental & Clinical Cancer Research CrossRef
19. Fluorescent Nanohybrids from ZnS/CdSe Quantum Dots Functionalized with Triantennary, N-Hydroxy-p-(4-arylbutanamido)benzamide/Gallamide Dendrons That Act as Inhibitors of Histone Deacetylase for Lung Cancer
    Chien-Tien Chen et al, 2021, ACS Applied Bio Materials CrossRef
20. Proteomic characterization of post-translational modifications in drug discovery
    Lin-hui Zhai et al, 2022, Acta Pharmacologica Sinica CrossRef
21. Singlet Anticancer Therapy Through Epi-Weapons Histone Deacetylase Inhibitors and Its Shortcomings
    Shabir Ahmad Ganai, 2020, Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy CrossRef